6,7,4'-Trihydroxyisoflavone

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

6,7,4'-三羟基异黄酮是一种新型 PKCα 抑制剂，可抑制太阳紫外线诱导的基质金属蛋白酶 1，具有抗氧化和抗癌活性。分子研究表明，6,7,4'-THIF 显着抑制乙酰胆碱酯酶东莨菪碱诱导的小鼠海马体和硫代巴比妥酸反应物质（TBARS）的活性。

6,7,4'-Trihydroxyisoflavone, is a novel inhibitor of PKCα in suppressing solar UV-induced matrix metalloproteinase 1, which has antioxidant, and anti-cancer activities.Molecular studies showed that 6,7,4'-THIF significantly inhibited acetylcholinesterase and thiobarbituric acid reactive substance (TBARS) activities in the hippocampus of scopolamine-induced mice.In addition, immunohistochemistry and Western blot results revealed that 6,7,4'-THIF significantly increased brain-derived neurotrophic factor (BDNF) and phosphor cAMP response element binding (CREB) in the hippocampus of mice.?A single administration of 6,7,4'-THIF significantly improved scopolamine-induced cognitive dysfunction in these in vivo tests.?Moreover, treatment with 6,7,4'-THIF alone enhanced learning and memory performance in the same behavioral tests. 6,7,4'-THIF improves cognitive dysfunction induced by scopolamine and enhances learning and memory by activation of the cholinergic system and the p-CREB/BDNF signaling pathway in mice.

Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppessesanchorage-dependent growth of HCT-116 and DLD1 cells in a dose- and time-dependent manner without cytotoxicity.Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppresses CDK1 activity in a dose-dependent manner andinhibits CDK2 activity in HCT-116 cells.Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) induces cell cycle arrest at the S and G2/M phases, the percentage of cells in S phase is higher in the 100 μM 6,7,4′-THIF-treated group, and the same pattern is observed in G2/M phase (29.5% versus 19.1% ) . Cell Viability Assay Cell Line:HCT-116 cells Concentration:0, 12.5, 25, 50 or 100 μM Incubation Time:24, 48 or 72 hours Result:Inhibited anchorage-dependent and -independent growth of HCT-116 cells.Western Blot Analysis Cell Line:HCT-116 and DLD1 cells Concentration:0, 25, 50 or 100 μM Incubation Time:48 hours Result:Inhibited CDK1,CDK2 expression.Cell Cycle Analysis Cell Line:HCT-116 cells Concentration:0, 25, 50 or 100 μM Incubation Time:24, 48 or 72 hours Result:Induces cell cycle arrest of HCT-116 cells at S and G2/M phases.

Desmethylglycitein (4',6,7-Trihydroxyisoflavone) (intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days) suppresses tumor development in mice and serves as an effective anticancer treatment with the potential to inhibit or delay the tumorigenicity of HCT-116 cells in an in vivo system. Animal Model:Female athymic nude mice subcutaneously injected with HCT-116 cells Dosage:5 or 25 mg/kg Administration:Intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days Result:Decreased tumor growth, volume and weight of HCT-116 xenografts.

——

Angiogenesis

PKC

CDK1|CDK2|PKC

——

——

17817-31-1

270.2

C15H10O5

>98% (HPLC)

DMSO:125 mg/mL (462.55 mM; Need ultrasonic)

O=C1C(C2=CC=C(O)C=C2)=COC3=CC(O)=C(O)C=C13

——

(-20℃)

With Ice Pack

≥ 2 years